Cambrex

Activities: Ingredients

Trending Articles

  1. Medac and chiron develop organ-on chip tech for animal free drug testing The companies aim to develop an animal-free pharmaceutical testing method that utilises organ-on chip technology, and will be used in rheumatoid arthritis drug testing
  2. Lonza expands bioconjugation capabilities for ADC manufacturing at Visp site The CDMO's facility will double its bioconjugate manufacturing capacity with two 1,200 L manufacturing suites
  3. Ascend Advanced Therapies expands US footprint through Advanced BioScience Laboratories merger Ascend's collaboration with EW Healthcare partners will expand its reach in the US pharmaceutical market through capital investment and an uptick in GMP AAV manufacturing capacity
  4. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
  5. Rousselot and IamFluidics launch dissolvable microcarrier for cell culturing The alginate and denatured collagen based product allows researchers to produce scalable cell cultures for biologic drugs and cell therapies

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

Related Content

Manufacturing

Cambrex optimises the peptide synthesis process with novel LPPS technology

The manufacturing solution reduces the reliance on specialised, solid-phase reactors, while being easily scalable and less resource-intensive
Distribution

Cambrex expands stability storage capabilities with novel US facility

The facility allows for pharmaceutical and medical device storage at a wide range of temperatures and humidity levels, serving the US market with next day delivery
Manufacturing

Cambrex completes expansion at small molecule API facility

The company has announced it has doubled the size of its small molecule active pharmaceutical ingredient (API) manufacturing facility
Manufacturing

Cambrex completes Snapdragon Chemistry acquisition

The company continues to expand its portfolio of specialised solutions for pharmaceutical development and manufacturing
Manufacturing

Cambrex set to acquire Snapdragon Chemistry

“The acquisition of Snapdragon will accelerate our growth in the area of continuous flow process development and manufacturing"
Manufacturing

Cambrex invests in 21,000 sqft R&D facility in Minnesota

The facility is located on a 45-acre property and produces a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances
Manufacturing

Cambrex expands its stability storage business

Named Q1 Scientific, the service offers environmentally-controlled stability storage services to the pharmaceutical, medical device and life sciences industries
Subscribe now